Drugs / Antibody Therapy
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02620865 | Dec 2015 → Jun 2021 | pancreatic adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antibody Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02620865 ↗ |
| Known as | BATs | “activated T cells (BATs)” NCT02620865 ↗ |
| Action | Deplete | “seek out, attach to, and kill more cancer cells” NCT02620865 ↗ |
| Modality | Cell therapy | “patient's own T cells that are coated with a bispecific antibody” NCT02620865 ↗ |
| Route | Intravenous | “anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV” NCT02620865 ↗ |
| Target | EGFR | “epidermal growth factor receptor (EGFR) bispecific antibody” NCT02620865 ↗ |